183 related articles for article (PubMed ID: 31956236)
1. "4+7" city drug volume-based purchasing and using pilot program in China and its impact.
Tang M; He J; Chen M; Cong L; Xu Y; Yang Y; Hou Z; Song P; Jin C
Drug Discov Ther; 2019; 13(6):365-369. PubMed ID: 31956236
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls.
Chen Y; Ji X; Xiao H; Unger JM; Cai Y; Mao Z; Yeung K
Front Pharmacol; 2021; 12():804237. PubMed ID: 35815118
[TBL] [Abstract][Full Text] [Related]
3. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
4. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N; Yang Y; Xu L; Mao Z; Cui D
BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
[TBL] [Abstract][Full Text] [Related]
5. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
6. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
[TBL] [Abstract][Full Text] [Related]
7. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China.
Chen L; Yang Y; Luo M; Hu B; Yin S; Mao Z
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33334027
[TBL] [Abstract][Full Text] [Related]
8. Short-term differences in drug prices after implementation of the national essential medicines system: A case study in rural Jiangxi Province, China.
Wang J; Liu X; Wang S; Chen H; Wang X; Zhou W; Wang L; Zhu Y; Zheng X; Hao M
Indian J Pharmacol; 2015; 47(5):535-9. PubMed ID: 26600644
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effectiveness of comprehensive drug price reform: a case study from Shihezi city in Western China.
Lin T; Wu Z; Liu M; Wu X; Zhang X
Int J Equity Health; 2020 Aug; 19(1):133. PubMed ID: 32762691
[TBL] [Abstract][Full Text] [Related]
10. The Impact of the National Nutrition Program 2017-2030 on People's Food Purchases: A Revenue-Based Perspective.
Chen J; Yang CC
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578908
[TBL] [Abstract][Full Text] [Related]
11. Can low-carbon cities increase urban housing prices? Evidence from China's low-carbon city pilot.
Li L; Wang H; Guo C; Ning J
Environ Sci Pollut Res Int; 2023 Oct; ():. PubMed ID: 37831252
[TBL] [Abstract][Full Text] [Related]
12. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.
Wen X; Yin S; Cui L; Mao L; Lin Z; Yaermaimaiti Z; Geng X; Li Y; Yang Y; Cui D; Mao Z
Front Public Health; 2021; 9():718013. PubMed ID: 34760861
[No Abstract] [Full Text] [Related]
13. Exploration of approaches to adjusting brand-name drug prices in Mainland of China: based on comparison and analysis of some brand-name drug prices of Mainland and Taiwan, China.
Weng G; Han S; Pu R; Pan WH; Shi L
Chin Med J (Engl); 2014; 127(12):2222-8. PubMed ID: 24931232
[TBL] [Abstract][Full Text] [Related]
14. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Yang Y; Chen L; Ke X; Mao Z; Zheng B
BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
[TBL] [Abstract][Full Text] [Related]
15. Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China.
Xing Q; Tang W; Li M; Li S
Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35409966
[TBL] [Abstract][Full Text] [Related]
16. Spillover effect analysis of home-purchase limit policy on housing prices in large and medium-sized cities: Evidence from China.
Wu G; Guo W; Niu X
PLoS One; 2023; 18(1):e0280235. PubMed ID: 36626388
[TBL] [Abstract][Full Text] [Related]
17. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Liu Y; Yi H; Fang K; Bao Y; Li X
Front Public Health; 2022; 10():942638. PubMed ID: 35937254
[TBL] [Abstract][Full Text] [Related]
18. Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurement.
Chen M; Cong L; He J; Yang Y; Xu Y; Tang M; Jin C
Drug Discov Ther; 2020 Jul; 14(3):145-148. PubMed ID: 32536620
[TBL] [Abstract][Full Text] [Related]
19. The impact of the reference pricing policy in China on drug procurement and cost.
Jiang B; Zhou RJ; Feng XL
Health Policy Plan; 2022 Jan; 37(1):73-99. PubMed ID: 34379765
[TBL] [Abstract][Full Text] [Related]
20. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
